Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours


Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.

Aim(s): We sought to determine the most sensitive and specific biomarker for screening for CHD.

Materials and methods: Patients underwent echocardiography and blood sampling for analysis of Chromogranin A and B, N-terminal-pro-BNP (NT-proBNP) and plasma 5-Hydroxyindoleacetic acid (5HIAA). CHD was defined as thickened, regurgitant right-sided valve, and quantified using a validated scoring system (Bhattacharyya, 2008).


Presenting Author:

Authors: Dobson R, Burgess M, Pritchard M, Vora J, Valle J,

Keywords: carcinoid heart disease, biomarkers,

To read the full abstract, please log into your ENETS Member account.